[间变性淋巴瘤激酶阳性非小细胞肺癌新辅助靶向治疗的进展]
[Advances of Neoadjuvant Targeted Therapy in ALK-positive Non-small Cell Lung Cancer].
作者信息
Sun Weizhen, Zhou Yuheng, Lin Yaobin, Feng Shoucheng, Long Hao
机构信息
Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou 510000, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2024 Nov 20;27(11):849-854. doi: 10.3779/j.issn.1009-3419.2024.106.30.
Abstract
Lung cancer remains the most frequently diagnosed cancer and the leading cause of cancer-related death worldwide, with anaplastic lymphoma kinase (ALK) fusion mutations accounting for approximately 4%-9% of cases. In recent years, there are increasing clinical evidences suggesting that the combination of ALK inhibitors with surgical treatment holds significant potential for clinical application in resectable early and locally advanced non-small cell lung cancer (NSCLC) patients. This review aims to summarize the advances in neoadjuvant targeted therapy for ALK fusion positive NSCLC and discuss its advantages and challenges in clinical practice. .
摘要
肺癌仍然是全球最常被诊断出的癌症以及癌症相关死亡的主要原因，间变性淋巴瘤激酶（ALK）融合突变约占病例的4%-9%。近年来，越来越多的临床证据表明，ALK抑制剂与手术治疗相结合在可切除的早期和局部晚期非小细胞肺癌（NSCLC）患者的临床应用中具有巨大潜力。本综述旨在总结ALK融合阳性NSCLC新辅助靶向治疗的进展，并讨论其在临床实践中的优势和挑战。
相似文献
1
[Advances of Neoadjuvant Targeted Therapy in ALK-positive Non-small Cell Lung Cancer].[间变性淋巴瘤激酶阳性非小细胞肺癌新辅助靶向治疗的进展]
Zhongguo Fei Ai Za Zhi. 2024 Nov 20;27(11):849-854. doi: 10.3779/j.issn.1009-3419.2024.106.30.
2
The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).间变性淋巴瘤激酶（ALK）在非小细胞肺癌（NSCLC）中的作用和治疗靶点。
Mol Cancer. 2018 Feb 19;17(1):52. doi: 10.1186/s12943-018-0810-4.
3
Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.针对晚期非小细胞肺癌中间变性淋巴瘤激酶酪氨酸激酶抑制剂的耐药谱：一项使用靶向下一代测序的多中心研究。
Eur J Cancer. 2021 Oct;156:1-11. doi: 10.1016/j.ejca.2021.06.043. Epub 2021 Aug 13.
4
Treatment of ALK-positive nonsmall cell lung cancer: recent advances.ALK 阳性非小细胞肺癌的治疗：最新进展。
Curr Opin Oncol. 2018 Mar;30(2):84-91. doi: 10.1097/CCO.0000000000000431.
5
Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review.新辅助靶向治疗后非小细胞肺癌手术的安全性：叙事性综述。
Int J Mol Sci. 2021 Nov 12;22(22):12244. doi: 10.3390/ijms222212244.
6
Refining precision cancer therapy in ALK-positive NSCLC.优化ALK阳性非小细胞肺癌的精准癌症治疗
EBioMedicine. 2019 Mar;41:9-10. doi: 10.1016/j.ebiom.2019.01.059. Epub 2019 Feb 6.
7
Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer.非小细胞肺癌中的间变性淋巴瘤激酶抑制剂
Curr Drug Targets. 2016;17(6):739-45. doi: 10.2174/1573399811666150615144336.
8
Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine.精准医学时代下 ALK 阳性非小细胞肺癌的序贯盲法治疗决策。
Clin Transl Oncol. 2020 Sep;22(9):1425-1429. doi: 10.1007/s12094-020-02290-1. Epub 2020 Jan 18.
9
[Clinical practice guideline on anaplastic lymphoma kinase-tyrosine kinase inhibitors for non-small cell lung cancer (2025 edition)].[间变性淋巴瘤激酶 - 酪氨酸激酶抑制剂治疗非小细胞肺癌临床实践指南（2025年版）]
Zhonghua Zhong Liu Za Zhi. 2025 Apr 23;47(4):283-297. doi: 10.3760/cma.j.cn112152-20241130-00546.
10
Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study.中国北方地区初诊晚期非小细胞肺癌患者 EGFR/ALK 基因状态及一线靶向治疗率的真实世界数据：一项前瞻性观察研究。
Thorac Cancer. 2019 Jul;10(7):1521-1532. doi: 10.1111/1759-7714.13090. Epub 2019 May 29.
本文引用的文献
1
Lorlatinib Versus Crizotinib in Patients With Advanced -Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.洛拉替尼对比克唑替尼用于治疗晚期 ALK 阳性非小细胞肺癌患者：III 期 CROWN 研究的 5 年结果。
J Clin Oncol. 2024 Oct 10;42(29):3400-3409. doi: 10.1200/JCO.24.00581. Epub 2024 May 31.
2
Alectinib in Resected -Positive Non-Small-Cell Lung Cancer.阿来替尼治疗可切除阳性非小细胞肺癌。
N Engl J Med. 2024 Apr 11;390(14):1265-1276. doi: 10.1056/NEJMoa2310532.
3
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC.评估新辅助免疫检查点阻断在可切除 NSCLC 中的随机对照试验中主要病理缓解和病理完全缓解作为生存替代终点。
J Thorac Oncol. 2024 Jul;19(7):1108-1116. doi: 10.1016/j.jtho.2024.03.010. Epub 2024 Mar 8.
4
Cancer statistics, 2024.2024年癌症统计数据。
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17.
5
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.帕博利珠单抗用于早期非小细胞肺癌的围手术期治疗。
N Engl J Med. 2023 Aug 10;389(6):491-503. doi: 10.1056/NEJMoa2302983. Epub 2023 Jun 3.
6
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.新辅助纳武利尤单抗联合化疗治疗可切除肺癌。
N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11.
7
Catalog of 5' Fusion Partners in -positive NSCLC Circa 2020.2020年左右阳性非小细胞肺癌中5'融合伙伴目录
JTO Clin Res Rep. 2020 Feb 19;1(1):100015. doi: 10.1016/j.jtocrr.2020.100015. eCollection 2020 Mar.
8
Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis.洛拉替尼与阿来替尼治疗亚洲和非亚洲患者ALK重排阳性晚期非小细胞肺癌的疗效和安全性比较：一项系统评价和网状Meta分析
Cancers (Basel). 2021 Jul 23;13(15):3704. doi: 10.3390/cancers13153704.
9
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial.Ⅱ期、开放标签、单臂、多中心研究，评估阿来替尼作为可手术切除 III 期 ALK 阳性 NSCLC 的新辅助治疗的疗效和安全性：ALNEO 试验。
Clin Lung Cancer. 2021 Sep;22(5):473-477. doi: 10.1016/j.cllc.2021.02.014. Epub 2021 Feb 24.
10
Feasibility and Safety of Neoadjuvant Alectinib in a Patient With ALK-Positive Locally Advanced NSCLC.新辅助阿来替尼治疗ALK阳性局部晚期非小细胞肺癌患者的可行性和安全性
J Thorac Oncol. 2020 Jun;15(6):e95-e99. doi: 10.1016/j.jtho.2019.12.133.
Zotero 插件